RESEARCH Open Access

Periostin and TNF-a expression levels in peripheral blood of patients with acute cerebral infarction combined with obstructive sleep apnea syndrome and their predictive value for clinical prognosis

Yu Xin, Shuai Li, Huimin Liu and Bo Liu*

Abstract

Objective: To detect the expression levels of periostin and tumour necrosis factor- α (TNF- α) in patients with acute cerebral infarction (ACI) combined with obstructive sleep apnea syndrome (OSAS) and to investigate their predictive value for clinical prognosis.

Methods: In this case–control study, serum periostin and TNF-α levels were measured using ELISA, and patients were scored on the National Institutes of Health Stroke Scale (NIHSS) and modified Rankin Scale (mRS). Receiver operating characteristic curve(ROC) were generated to analyse the effect of peripheral blood periostin and TNF-α levels on poor prognosis.

Results: NIHSS score, mRS score and peripheral blood periostin and TNF- α levels were higher in the observation group than in the control group (P < 0.001); serum periostin and TNF- α levels were positively correlated with the NIHSS score and mRS score (P < 0.001). Serum periostin and TNF- α levels were higher in patients with a poor prognosis than in those with a favourable prognosis (P < 0.001); the area under curve (AUC) values for the diagnosis of poor prognosis based on TNF- α , periostin or both factors were 0.868 (95% Cl: 0.781–0.954), 0.834 (95% Cl: 0.734–0.934), and 0.875 (95% Cl: 0.792 ~ 0.958), with sensitivities of 0.654, 0.846, and 0.654 and specificities of 0.944, 0.750, and 0.917, respectively.

Conclusion: Patients with ACI combined with OSAS have elevated peripheral blood periostin and TNF- α levels, and the combination of these two factors has high predictive value for poor prognosis.

Keywords: Acute cerebral infarction, Obstructive sleep apnoea syndrome, Periostin, Tumour necrosis factor-α, Clinical prognosis

Background

Stroke is the primary cause of disability and death in adults worldwide, and its prevalence is rising [1]. The most common type of stroke is acute cerebral infarction (ACI), which accounts for 69.6 to 70.8% of strokes in China [2]. Obstructive sleep apnea syndrome (OSAS) is a condition in which the upper airway muscles collapse during sleep at night, partially or completely obstructing the airway [3]. In 2011, the American Heart and Stroke Association listed sleep

Department of Neurology, The First Affiliated Hospital of Baotou Medical College, Baotou 014010, Inner Mongolia, China



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

^{*}Correspondence: liu_bo2006@126.com

Xin et al. BMC Neurology (2022) 22:358 Page 2 of 6

apnea as a risk factor for the primary prevention of stroke [4], and the comorbidity rate of stroke and OSAS is as high as 70% [5]. The pathogenic mechanisms of OSAS, such as chronic intermittent hypoxia, sympathetic activation, changes in brain autoregulation, oxidative stress, systemic inflammation, a hypercoagulable state and endothelial dysfunction, increase the risk of stroke [6]. Patients with stroke combined with OSAS have severe neurological deficits, leading to prolonged hospitalization and rehabilitation and increased risks of stroke recurrence, morbidity and mortality [7]. TNF- α is a central element in the regulation of systemic inflammation and plays a vital role in ischaemiareperfusion injury caused by the rapid release of various cytokines [8]. Periostin is also an important proinflammatory cytokine in vivo. Both TNF-α and periostin can regulate each other and participate in a series of inflammatory responses in vivo that are involved in the pathogenesis of many diseases; moreover, these two factors may be potential biomarkers for assessing the severity of OSAS [9]. The correlation between periostin and TNF- α levels and the severity of OSAS in patients with ACI is unclear. This study aimed to investigate serum periostin and TNF-α levels in patients with ACI combined with OSAS and their relationship with prognosis for clinical reference.

Materials and methods

General data

One hundred and seven patients with ACI who were hospitalized in the Department of Neurology of the First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology, between June 2021 and June 2022 were recruited. Inclusion criteria: (1) stroke symptom onset < 72 h and brain tissue damage confirmed by cranial magnetic resonance imaging (MRI); and (2) ability to participate in completing the scales and neurological examination. Exclusion criteria: (1) history of malignancy; (2) acute or chronic infection; (3) autoimmune disease; (4) previous severe physical disability or mental illness; and (5) alcohol or drug dependence. The study was approved by the Ethics Committee of the Research Project of the First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology (20210008), and all enrolled patients provided written informed consent.

Grouping

All the patients underwent polysomnography (PSG) within one week of admission to determine whether they had combined OSAS, and the main observation indexes were apnea hypopnea index (AHI) and minimum oxygen saturation (LSaO2). The PSG device has Grael specifications and was produced by Comumedics, and the results were analysed by a practitioner with the relevant sleep

study qualification. The patients were divided into the ACI combined with OSAS group (observation group) and the ACI alone group (control group) according to the sleep monitoring results. The observation group was divided into the good prognosis group and the poor prognosis group according to the mRS score.

Research methods

Clinical data collection

General data were collected on admission, including demographic information (name, sex, age, height, weight, BMI, etc.), past medical history (hypertension, diabetes, heart disease, etc.), symptoms, and polysomnographic monitoring data.

Serum periostin and TNF-a levels and other blood indicators

Five millilitres of fasting peripheral venous blood was collected on the morning of the second day of admission. The samples were centrifuged at $1000 \times g$ for 20 min after 2 h at room temperature, and the supernatant was extracted to detect serum periostin and TNF- α levels by enzyme-linked immunosorbent assay (ELISA) kits (Shanghai Jianglai Biotechnology Co) according to the kit instructions. Blood glucose, lipids and other relevant indicators were tested at the same time.

Severity assessment

Patients were assessed for ischaemic stroke severity using the National Institutes of Health Stroke Scale (NIHSS) within 24 h of admission.

Clinical prognosis assessment

The clinical prognosis of patients with neurological deficits was evaluated using the mRS on day 14 of disease onset, with patients scoring 0 to 2 placed in the good prognosis group and those scoring 3 to 6 placed in the poor prognosis group.

Statistical analyses

Data with a normal distribution are presented as the mean \pm standard deviation, and differences between groups were compared using the Student's t test; data that did not conform to a normal distribution are presented as the median (25th percentile, 75th percentile), and differences between groups were compared using the Mann–Whitney U test. SPSS 20.0 statistical software was used for analysis. P < 0.05 was considered to indicate statistical significance.

Results

Comparison of general data

A total of 107 patients with ACI were included in the study. Sixty-two patients met the criteria for OSAS

Xin et al. BMC Neurology (2022) 22:358 Page 3 of 6

Table 1 Demographic information for the two groups

Projects	ACI and OSAS group (n = 62)	ACI only group (n = 45)	Test value	P value
Sex [male, cases (%)]	40 (64.5)	27 (60.0)	2.636	0.621
Age (years)	61.68 ± 10.88	60.53 ± 12.71	0.500	0.618
BMI (kg/m ²)	25.5 (23.9, 28.15)	24.8 (23.65, 27.3)	-1.196	0.232
Hypertension history [n, cases (%)]	52 (83.9)	34 (75.6)	1.143	0.285
Diabetes history [n, cases (%)]	16 (25.8)	4 (8.9)	4.910	0.027
Cardiac history [n, cases (%)]	7 (11.3)	5 (11.1)	0.001	0.977
Presence of neck plaques [n, cases (%)]	61 (98.4)	43 (95.6)	32.59	0.381
Blood glucose (mmol/L)	5.85 (5.00, 7.75)	5.1 (4.9, 5.5)	-3.423	0.001
Total cholesterol (mmol/L)	4.66 ± 1.04	4.53 ± 0.90	0.665	0.507
Triglycerides (mmol/L)	1.63 (1.31, 2.31)	1.43 (1.21, 1.94)	-1.174	0.240
High-density lipoprotein (mmol/L)	1.05 (0.92, 1.25)	1.11 (0.93, 1.28)	-0.761	0.447
Low-density lipoprotein (mmol/L))	3.03 ± 0.90	2.99 ± 0.82	0.238	0.812
Uric acid (µmol/L)	294 (232.25, 369)	324 (270, 397)	-1.660	0.097
Creatinine (µmol/L)	68 (53.75, 81.25)	73 (60.5, 84)	-0.761	0.447
AHI (times/h)	18.6 (12.45, 38.8)	3 (1, 4)	-8.770	< 0.001
saO ₂ (%) 81 (71.5, 85)		89 (87, 90.5)	-7.099	< 0.001
NIHSS score	4.5 (2, 9.25)	1 (1, 4)	-4.907	< 0.001
mRS score	2 (1, 4)	1 (1, 2)	-3.441	0.001

Note: Data that do not conform to a normal distribution are presented as the M (25th percentile, 75th percentile); data that conform to a normal distribution are presented as the mean \pm standard deviation

Table 2 Comparison of serum levels of periostin and TNF-α in the 2 groups

Indicator	ACI and OSAS group (n = 62)	ACI only group (n=45)	Z	P value
Periostin (ng/mL)	11.04 (10.49, 11.42)	8.49 (7.80, 9.23)	-8.654	< 0.001
TNF-a (pg/mL)	126.85 (100.73, 167.90)	69.4 (59.97, 77.82)	-8.514	< 0.001

(observation group), and 45 patients did not meet the criteria (control group). There were no significant differences between these groups of patients in terms of age, sex or BMI. However, the diagnosis of diabetes was significantly more frequent in the observation group than in the control group, and blood glucose levels were significantly higher in the observation group than in the control group (P=0.027). The NIHSS score and mRS score were higher in the observation group than in the control group (P<0.001). The demographic data are summarized in Table 1.

Comparison of serum periostin and TNF- α levels in the 2 groups

Serum periostin and TNF- α levels were significantly higher in the observation group than in the control group (P<0.001) (Table 2).

 $\begin{tabular}{ll} \textbf{Table 3} & \mbox{Correlation between serum periostin and TNF-α levels and NIHSS and mRS scores \\ \end{tabular}$

Indicator	NIHSS score		mRS score	
	r	P	r	P
Periostin	0.508*	< 0.001	0.571*	< 0.001
TNF-a	0.683*	< 0.001	0.677*	< 0.001

Note: *Indicates a significant correlation at the level of 0.01 (two-sided)

Correlation between serum periostin and TNF- α levels and NIHSS and mRS scores

Pearson correlation coefficient analysis showed that serum periostin and TNF- α levels were positively correlated with the NIHSS score and mRS score (P<0.001), as shown in Table 3.

Xin et al. BMC Neurology (2022) 22:358 Page 4 of 6

Comparison of periostin and TNF- α levels in peripheral blood between the good prognosis group and the poor prognosis group

In the observational group, 58% of the patients (36 of 62) had a good prognosis (mRS score < 2), and 42% (26 of 62) had a poor prognosis (mRS score between three and six). Periostin and TNF- α levels in peripheral blood were significantly higher in the poor prognosis group than in the good prognosis group (P<0.001) (Table 4).

Ability of serum periostin and TNF- α levels to predict a poor clinical prognosis for ACI combined with OSAS

Binary logistic regression established a combined predictive model of periostin and TNF- α , and the area under curve (AUC) of TNF- α , periostin and their combination for the ability to predict a poor prognosis was 0.868 (95% CI: 0.781 ~ 0.954), 0.834 (95% CI: 0.734 ~ 0.934), and 0.875 (95% CI: 0.792 ~ 0.958), respectively (Table 5 and Fig. 1).

Discussion

OSAS is an independent risk factor for the development of stroke. OSAS causes a hypercoagulable state in the blood through chronic hypoxia and an inflammatory response, resulting in increased erythrocytes, platelet aggregation, and increased levels of fibrinogen and adhesion molecules [10]; these factors further aggravate ischaemia and hypoxia in brain tissue and damage vascular smooth muscle, thereby increasing the risk of stroke [11, 12]. The results of this study showed that the NIHSS score and mRS score were higher in the observation group than in the control group, indicating that the neurological deficits were more severe in ACI patients with combined OSAS.

Table 4 Comparison of serum TNF-α and periostin levels in patients with ACI and OSAS but with different prognoses

Group	n	Periostin (ng/mL)	TNF-α (pg/mL)
Good prognosis group	36	9.88 (7.90, 10.58)	130.84 (81.02, 178.37)
Poor prognosis group	26	11.12 (9.18, 11.53)	83.7 (69.4, 109.76)
Z/P value	-	-4.466/<0.001	-4.908/<0.001


Inflammation is a fundamental pathogenic factor in the development of atherosclerosis [13], and both periostin and TNF-α are important proinflammatory cytokines involved in the inflammatory response that can regulate each other to promote an inflammatory response [9]. Periostin is an extracellular matrix protein that regulates smooth muscle cells and foam cells and mediates atherosclerotic plaque formation [14], and increased serum periostin is thought to correlate with the severity of large atherosclerotic strokes [15]. Periostin has been shown to promote the proliferation and differentiation of neural stem cells in the brain after ischaemic or haemorrhagic injury, and in addition to exerting neuroprotective effects, increased serum periostin levels may promote microangiogenesis and prevent ischaemic injury after stroke [15, 16]. In this study, by comparing peripheral blood periostin levels in patients with ACI with and without coexisting OSAS, we found that peripheral blood periostin levels were significantly higher in patients with ACI combined with OSAS and were positively correlated with the NIHSS and mRS scores. The findings suggested more brain tissue damage in patients with ACI and OSAS compared to those with ACI alone, presumably through the binding of the fasciclin I structural domain of periostin to tenascin C (TNC) and subsequent coordinate regulation, causing blood-brain barrier disruption [17]. Periostin may also activate the intracellular MAPK signalling pathway through integral proteins, and MAPKs induce and activate downstream matrix metalloproteinase-9 to degrade brain microvascular basal lamina and tight junction protein-1, leading to blood-brain barrier disruption and brain oedema formation [18]. The former allows periostin to enter the circulation through the damaged blood-brain barrier, causing elevated periostin levels in peripheral blood.

TNF- α is a proinflammatory cytokine with multiple biological activities that is involved in various pathological processes, such as the inflammatory response and immune response [19]. Intermittent hypoxia (IH) during sleep in OSAS patients is the main pathophysiological mechanism of systemic multisystem injury, leading to oxidative imbalance, increased oxygen free radicals, and the activation of proinflammatory cellular mediators such as hypoxia inducible factor- 1α (HIF- 1α), the most

Table 5 The prognostic value of the two factors for the diagnosis of ACI with OSAS

. 3						
Indicator	Optimal cut-off value	AUC	Sensitivity (%)	Specificity (%)	95% CI	P value
Periostin	11.105	0.834	84.6	75	0.734~0.934	< 0.001
TNF-a	157.255	0.868	65.4	94.4	0.781~0.954	< 0.001
Periostin and TNF-α combined	-	0.875	65.4	91.7	0.792~0.958	< 0.001

Xin et al. BMC Neurology (2022) 22:358 Page 5 of 6



critical nuclear transcription factor that mediates the cellular hypoxic response; HIF-1 levels are influenced by the degree of tissue hypoxia. HIF-1α is activated during hypoxia and then promotes the transcription of its downstream target gene TNF-α, resulting in a series of stress responses to hypoxia [8, 20]. TNF- α also induces the production of reactive oxygen species (ROS), which drive the redox reactions that constitute "ROS signalling"; these ROS may also cause oxidative stress and lead to vascular dysfunction [21]. It has been shown that brain cell necrosis, increased blood-brain barrier permeability, and increased TNF- α levels in focal areas of brain tissue after ACI lead to increased infarct size and brain damage [22]. The results of this study showed that peripheral blood TNF-α levels were significantly elevated in patients with ACI combined with OSAS and were positively correlated with the NIHSS and mRS scores, indicating that inflammation was aggravated by the occurrence of ACI and OSAS. In addition, intermittent hypoxia/reoxygenation (IHR) can also activate the TLR4/NF-κB signalling pathway, leading to inflammation and thus the upregulation of TNF- α , a downstream inflammatory factor [23]. TNF- α induces the expression of periostin through the transcription factor c-Jun [24], which is consistent with the results of the present study, in which Pearson correlation analysis showed that periostin was significantly positively correlated with TNF-α. Moreover, the current study showed that the release of periostin and TNF-α may trigger an inflammatory cascade response, thereby aggravating brain tissue damage. In addition, the AUC values for the ability of periostin and TNF-α to predict an adverse prognosis of ACI combined with OSAS were 0.834 and 0.868, respectively, indicating some predictive value for adverse prognosis. Further analysis showed that the AUC value for the 2 factors combined was 0.875; the predictive value of the combination was better than that of the individual factors. In addition, analysis of the relationship between periostin and TNF-α levels and the prognosis of ACI combined with OSAS showed that the incidence of poor prognosis was high among patients with high levels of periostin and TNF- α in peripheral blood, with severe neurological deficits and more serious consequences in

Xin et al. BMC Neurology (2022) 22:358 Page 6 of 6

the absence of timely treatment. The detection of peripheral blood periostin and TNF- α levels can help to determine and predict the condition and prognosis of patients with ACI combined with OSAS.

In summary, elevated peripheral blood periostin and TNF- α levels are observed in patients with ACI and coexisting OSAS and are associated with poor clinical outcomes. The measurement of periostin and TNF- α levels could be beneficial in predicting the outcome of patients with ACI and OSAS.

Acknowledgements

We thank the participants who took part in this study. We would like to thank Editage for English language editing.

Authors' contributions

Yu Xin and Bo Liu wrote the main manuscript text. Shuai Li and Huimin Liu mainly collected, analysed and processed data and drew the tables. All authors reviewed the manuscript. The author(s) read and approved the final manuscript.

Funding

This study was supported by grants from the Inner Mongolia Higher Education Science and Technology Research Project (NJZZ22076).

Availability of data and materials

All data generated and analysed during this study for this report are included in this published article. Additional study data can be requested from the corresponding author upon request.

Declarations

Ethics approval and consent to participate

In this experiment, we used human peripheral blood samples, and this experiment was performed in accordance with the principles of medical ethics and the Declaration of Helsinki. The experimental protocol was approved by the Medical Ethics Committee of the First Affiliated Hospital of Baotou Medical College, Grant No. 20210008. During the collection of peripheral blood, we confirmed that informed consent was obtained from all subjects and/or their legal quardians.

Consent for publication

Not applicable.

Competing interests

The authors have no conflicts of interest to declare.

Received: 22 June 2022 Accepted: 12 September 2022 Published online: 20 September 2022

References

- GBD 2019 Stroke Collaborators. Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol. 2021;20(10):795–820.
- Wang W, Jiang B, Sun H, Ru X, Sun D, Wang L, Wang L, Jiang Y, Li Y, Wang Y, Chen Z, Wu S, Zhang Y, Wang D, Wang Y, Feigin VL, NESS-China Investigators. Prevalence, incidence, and mortality of stroke in China: results from a Nationwide Population-Based Survey of 480687 Adults. Circulation. 2017;135(8):759–71.
- Gottlieb DJ, Punjabi NM. Diagnosis and management of obstructive sleep apnea: a review. JAMA. 2020;323(14):1389–400.
- 4. Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, Biller J, Brown M, Demaerschalk BM, Hoh B, Jauch EC, Kidwell CS, Leslie-Mazwi TM, Ovbiagele B, Scott PA, Sheth KN, Southerland AM, Summers DV, Tirschwell DL. Guidelines for the early management of patients with acute

- ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2019;50(12):e344–418.
- Seiler A, Camilo M, Korostovtseva L, et al. Prevalence of sleep-disordered breathing after stroke and TIA:a meta-analysis. Neurology. 2019;92(7):e648–54.
- Tanayapong P, Kuna ST. Sleep disordered breathing as a cause and consequence of stroke: a review of pathophysiological and clinical relationships. Sleep Med Rev. 2021;30(59):101499.
- Kumar R, Suri JC, Manocha R. Study of association of severity of sleep disordered breathing and functional outcome in stroke patients. Sleep Med. 2017;34:50–6.
- Maniaci A, lannella G, Cocuzza S, Vicini C, Magliulo G, Ferlito S, Cammaroto G, Meccariello G, De Vito A, Nicolai A, Pace A, Artico M, Taurone S. Oxidative stress and inflammation biomarker expression in obstructive sleep apnea patients. J Clin Med. 2021;10(2):277.
- Ji L, Liu Y, Liu P, Ji G, He J, Gan Y, Zhu S, Chen B, Zhang W. Serum periostin and TNF-α levels in patients with obstructive sleep apnea-hypopnea syndrome. Sleep Breath. 2021;25(1):331–7.
- 10 Gabryelska A, Lukasik ZM, Makowska JS, Bialasiewicz P. Obstructive Sleep apnea: from intermittent hypoxia to cardiovascular complications via blood platelets. Front Neurol. 2018;9:635.
- Tanayapong P, Kuna ST. Sleep disordered breathing as a cause and consequence of stroke: a review of pathophysiological and clinical relationships. Sleep Med Rev. 2021;59:101499.
- Gonzalez-Aquines A, Martinez-Roque D, Baltazar Trevino-Herrera A, Chavez-Luevanos BE, Guerrero-Campos F, Gongora-Rivera F. Sindrome de apnea obstructiva del sueño y su relacion con el ictus isquemico [Obstructive sleep apnea syndrome and its relationship with ischaemic stroke]. Rev Neurol. 2019;69(6):255–60.
- Ammirati E, Moroni F, Norata GD, Magnoni M, Camici PG. Markers of inflammation associated with plaque progression and instability in patients with carotid atherosclerosis. Mediators Inflamm. 2015;2015:718329.
- 14 Liu AY, Zheng H, Ouyang G. Periostin, a multifunctional matricellular protein in inflammatory and tumor microenvironments. Matrix Biol. 2014;37:150–6.
- He X, Bao Y, Shen Y, Wang E, Hong W, Ke S, Jin X. Longitudinal evaluation of serum periostin levels in patients after large-artery atherosclerotic stroke: a prospective observational study. Sci Rep. 2018;8(1):11729.
- Hixson JE, Shimmin LC, Montasser ME, Kim DK, Zhong Y, Ibarguen H, Follis J, Malcom G, Strong J, Howard T, Langefeld C, Liu Y, Rotter JI, Johnson C, Herrington D. Common variants in the periostin gene influence development of atherosclerosis in young persons. Arterioscler Thromb Vasc Biol. 2011;31(7):1661–7.
- Kawakita F, Suzuki H. Periostin in cerebrovascular disease. Neural Regen Res. 2020;15(1):63–4.
- Liu L, Kawakita F, Fujimoto M, Nakano F, Imanaka-Yoshida K, Yoshida T, Suzuki H. Role of Periostin in Early Brain Injury After Subarachnoid Hemorrhage in Mice. Stroke. 2017;48(4):1108–11.
- Aggarwal BB, Gupta SC, Kim JH. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood. 2012;119(3):651–65.
- 20. Taabazuing CY, Hangasky JA, Knapp MJ. Oxygen sensing strategies in mammals and bacteria. J Inorg Biochem. 2014;133:63–72.
- Lamb FS, Choi H, Miller MR, Stark RJ. TNF-α and Reactive Oxygen Signaling in Vascular Smooth Muscle Cells in Hypertension and Atherosclerosis. Am J Hypertens. 2020;33(10):902–13.
- Dabrowska S, Andrzejewska A, Kozlowska H, Strzemecki D, Janowski M, Lukomska B. Neuroinflammation evoked by brain injury in a rat model of lacunar infarct. Exp Neurol. 2021;336:113531.
- 23. Chen YL, Chen YC, Wang HT, Chang YT, Fang YN, Hsueh S, Liu WH, Lin PT, Hsu PY, Su MC, Huang KT, Lin MC. The impact of intermittent hypoxemia on left atrial remodeling in patients with obstructive sleep apnea syndrome. Life (Basel). 2022;12(2):148.
- Zhang ZR, Chen LY, Qi HY, Sun SH. Expression and clinical significance of periostin in oral lichen planus. Exp Ther Med. 2018;15(6):5141–7.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.